A Multicentre, Comparative, Open-label, Randomized, Phase III Study to Assess the Immunogenicity and Safety of EutravacTMinj (DTaP-HB Combined Vaccine) Administered at 2, 4, 6 Months of Age Compared With DTaP Vaccine at 2, 4, 6 Months of Age Combined with Monovalent Hepatitis B Vaccine Administered at Birth, 1, 6 Months of Age in Healthy Infants.
Phase of Trial: Phase III
Latest Information Update: 20 Jul 2013
At a glance
- Drugs DTaP-hepatitis B vaccine (Primary) ; DTaP vaccine; Hepatitis B vaccine
- Indications Diphtheria; Hepatitis B; Pertussis; Tetanus
- Focus Pharmacodynamics; Registrational
- 20 Jul 2013 New trial record